Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen lower as investors mull jobs data
(Sharecast News) - London stocks were set to fall at the open on Tuesday following a weak session in Asia, as investors mulled the latest UK jobs data. The FTSE 100 was called to open around 40 points lower.
Figures released earlier by the Office for National Statistics showed that unemployment ticked higher in the three months to September, while wage growth slowed.
The unemployment rate rose to 4.3% from 4% in the previous quarter, and versus expectations for a 4.1% increase.
Meanwhile, quarterly average earnings excluding bonuses were up 4.3% on the previous year, down from 4.9% and below expectations of 4.7%.
In corporate news, the battle for warehouse owner Tritax EuroBox looked over after Segro said it would not up its offer, leaving Canadian investment firm Brookfield as the winner subject to shareholder approval.
Segro also said it would buy a portfolio of six Tritax EuroBox assets from Brookfield following completion of the Brookfield Offer for €470m.
AstraZeneca reported a strong financial performance for the first nine months of the year, with a 19% increase in revenue driven by solid growth in oncology, CVRM, respiratory, and rare diseases, leading to upgraded full-year guidance.
The FTSE 100 pharma giant said it had also submitted a new biologics licence application for datopotamab deruxtecan in EGFR-mutated non-small cell lung cancer, informed by phase two and three trial data, while withdrawing a prior BLA for a broader indication.
Additionally, AstraZeneca announced positive phase three trial results for Koselugo in adults with neurofibromatosis type 1, as well as a $3.5bn investment to expand its research and development and manufacturing footprint in the United States.
Results were also out from Vodafone, BAE Systems and Drax, among others.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.